RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
The offering is expected to close on or about June 30, 2021, subject to customary closing conditions.
- The offering is expected to close on or about June 30, 2021, subject to customary closing conditions.
- The net proceeds to RegeneRx, after deducting placement agent fees and other offering expenses, are expected to be approximately $1.8 million.
- Roth Capital Partners is acting as the sole placement agent in this offering.
- The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws.